Kornimate/medical-research-clean huggingface dataset:
pilot randomized control trial to assess the impact of video education on postpartum care knowledge and attendance among pregnant individuals with diabetes

Conditions: Postpartum Care

Summary: each year in the united states, about 700 people die from pregnancy-related causes. more than half of these deaths occur after delivery, during what is often called the "fourth trimester." many of these deaths-up to 80%-are believed to be preventable. in the first week postpartum, the most common causes of death are heavy bleeding, high blood pressure, and infection. after the first week, heart problems such as cardiomyopathy are the leading causes of death. in addition to the risk of life-threatening complications, health issues like diabetes and high blood pressure during pregnancy can increase a person's risk of developing long-term conditions such as heart disease and type 2 diabetes. despite the importance of postpartum care, up to 40% of individuals do not attend their postpartum check-up. attendance is especially low among people who are younger, publicly insured, or from underserved communities. among individuals with diabetes in pregnancy, postpartum care is critical to monitor blood sugar levels, assess for type 2 diabetes, manage complications, and ensure long-term follow-up with a primary care provider. however, many do not attend this visit or receive recommended screenings. common reasons include feeling fine, time constraints, and a lack of understanding about the purpose of the visit. the study was conducted as a pilot randomized controlled trial at a tertiary care center among pregnant individuals with type 1, type 2, or gestational diabetes. participants were randomly assigned to receive either usual care or to watch a 3-minute animated video during a prenatal visit. after enrolling, all participants completed a baseline survey using a secure platform (redcap) assessing their knowledge about the postpartum period and care expectations. the video was available in english and spanish and covered key information about what to expect after delivery, warning signs for complications, and why postpartum care is important. immediately after viewing the video, participants in the intervention group repeated the knowledge-based questions to assess changes in their understanding. investigators reviewed the electronic medical records to assess postpartum visit scheduling and attendance. this study is designed to determine whether a brief, accessible educational video can improve postpartum care engagement among individuals with diabetes in pregnancy. if effective, this type of video intervention could be implemented more widely to improve maternal health outcomes, particularly in high-risk populations.


Eligibility criteria:
inclusion criteria: * diagnosis of type 1 diabetes, type 2 diabetes, or gestational diabetes * 28 weeks gestational age or later * 18-50 years of age * english or spanish speaking exclusion criteria: * none

Keywords: diabetes video education
a trial of shr-1210 (an anti-pd-1 inhibitor) in combination with folfox4 in subjects with advanced hcc who have never received prior systemic treatment.

Conditions: Advanced Hepatocellular Carcinoma

Summary: the study is being conducted to evaluate the efficacy and safety of shr-1210 plus folfox4 in subjects with advanced hcc who have never received prior systemic treatment compared to placebo plus folfox4. the primary study hyposis is that camrelizumab combined with folfox4 treatment can improve overall survival when compared with placebo in combination with folfox4 regimen.


Eligibility criteria:
inclusion criteria: has not received prior systemic treatment for their advanced/metastatic hcc. has measurable disease according to recist v1.1. ecog performance status of 0 or 1. child-pugh class a or b with 7 points. life expectancy of at least 12 weeks. hbv dna\<500 iu/ml. adequate organ function： male or female participants of childbearing potential must be willing to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drug. exclusion criteria: known fibrolamellar hcc, prior malignancy active with the previous 5 years except for locally curable cancers that have been apparently cured. known or occurrence of central nervous system (cns) metastases. ascites with clinical symptoms. known or evidence of gi hemorrhage within the past 6 months. known or occurrence of hemorrhage/ thrombus. suffered from grade ii or above myocardial ischemia or myocardial infarction, uncontrolled arrhythmias. grade iii\~iv cardiac insufficiency, according to nyha criteria or echocardiography check: lvef\<50%. hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents (systolic blood pressure \> 150mmhg, diastolic blood pressure \> 90 mmhg). history of hepatic encephalopathy. known history of human immunodeficiency virus (hiv) infection. active infection or an unexplained fever \> 38.5°c during screening visits. prior or planning to organ transplantation including liver transplantation. interstitial lung disease that is symptomatic or may interfere with the detection and management of suspected drug-related pulmonary toxicity. proteinuria≥ 2+ and 24 hours total urine protein \> 1.0 g. active known, or suspected autoimmune disease. subjects with a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. any loco-regional therapy to liver (included but not limited: resection, radiotherapy, tae, tace, tai, rfa or pei) within 4 weeks prior to study. known history of hypersensitivity to monoclonal antibodies or any components of the study drugs. pregnant or breast-feeding women. according to the investigator, other conditions that may lead to stop the research.
long-term effects of scl-wearing on corneal neuromediators and postoperative rehabilitation after smile

Conditions: Contact Lens Complication; Small Incision Lenticule Extraction

Summary: to investigate the effects of neuromediators in corneal stromal lenticules from patients with long-term soft contact lens (scl) wear on corneal nerve regeneration and visual quality recovery following small incision lenticule extraction (smile).

he prospective cohort study recruited 90 patients who underwent smile between june 2023 and june 2024. 90 eyes were categorized into three groups according to the duration of wearing scl: the \> 10 years group (25 eyes), the ≤ 10 years group (35 eyes), and the non-wear (nw) group (30 eyes). pre- and post-operative assessments at 1, 3 and 6 months included corneal higher-order aberrations (hoas), corneal optical density, tear film breakup time (but), corneal fluorescein staining, subepithelial corneal nerve fiber parameters, ocular surface disease index (osdi), quality of vision (qov) scores, and contrast sensitivity function (csf). nerve growth factor (ngf), insulin-like growth factor binding protein-1 (igfbp-1), mesencephalic astrocyte-derived neurotrophic factor (manf), calcitonin gene-related peptide (cgrp) and substance p (sp) in stromal lenticules were quantified using elisa. multiple linear regression analysis was employed to evaluate the associations between scl wear duration, mediator levels, and postoperative outcomes.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years with stable refraction for at least two years; * corrected distance visual acuity of 20/20 or better; * no history of using rigid gas permeable lenses or orthokeratology (ok) lenses prior to examination exclusion criteria: - a history of moderate to severe dry eye as well as any ocular or systemic disease that would contraindicate laser refractive surgery.

Keywords: small incision lenticule extraction neuromediators visual quality corneal nerve regeneration soft contact lens
what lies beneath the stone? metabolic insights from composition-based analysis of kidney stones

Conditions: Urolithiasis, Calcium Oxalate

Summary: this retrospective observational study investigates the metabolic abnormalities associated with different types of kidney stones by analyzing their composition. the study includes adult patients diagnosed with urolithiasis, whose stone samples were analyzed using fourier transform infrared (ftir) spectroscopy. clinical, biochemical, and 24-hour urine metabolic parameters were compared between first-time and recurrent stone formers, and among subtypes of calcium oxalate stones (monohydrate vs. dihydrate). the goal is to identify metabolic risk factors that contribute to stone formation and recurrence, and to provide insights for individualized prevention strategies.

this retrospective study aims to evaluate the metabolic characteristics of patients with urolithiasis based on kidney stone composition. data were collected from patients treated for kidney stones between january 2010 and december 2024 at a tertiary urology center. stone analysis was performed using ftir spectroscopy, classifying stones into subtypes including calcium oxalate monohydrate (com), calcium oxalate dihydrate (cod), uric acid, and mixed types. serum levels of calcium, phosphorus, uric acid, creatinine, and parathyroid hormone (pth), along with 24-hour urine values (calcium, oxalate, citrate, uric acid, volume, and ph), were recorded. the study primarily compares metabolic differences between: first-time vs. recurrent stone formers com vs. cod stone subtypes findings from this study are expected to improve understanding of metabolic risk factors and contribute to the development of tailored metabolic evaluations and dietary or pharmacological preventive strategies for recurrent stone formers.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patients diagnosed with kidney stones between january 2010 and december 2024 * stone composition analyzed via fourier-transform infrared (ftir) spectroscopy * available metabolic panel including serum and 24-hour urine values exclusion criteria: * patients with secondary hyperparathyroidism, renal tubular acidosis, or other systemic metabolic diseases affecting stone formation * patients with incomplete medical records * patients with non-calcium-based stones (e.g., uric acid, struvite, cystine)

Keywords: calcium oxalate metabolic evaluation urolithiasis stone composition
a study of food effect on the pharmacokinetics of fuzuloparib capsules in chinese healthy adult subjects

Conditions: Solid Tumor

Summary: the objective of the study is to assess the effect of food on the pharmacokinetics, and safety of fuzuloparib capsules in healthy subject.


Eligibility criteria:
inclusion criteria: 1. healthy male and female subjects over 18 years; 2. body weight ≥ 50.0 kg for men and ≥ 45.0 kg for women, and body mass index (bmi) of 19.0 to 26.0 kg /m2 (inclusive); 3. participants should have no fertility plan from signing the informed consent until 6 months after the last dose, and take effective contraceptive measures. exclusion criteria: 1. subjects with evidence of disease or major surgery; 2. history of drug allergy; 3. treatment with other investigational drug within 3 months, use of any prescription drugs, chinese herbal supplements within 4 weeks, and/or need to use any over-the-counter (otc), food supplements within 2 weeks before the first dose or during the trial; 4. subjects refuse to stop drinking xanthine-rich beverages or foods at 48 hours before the first dose until the end of the study, and subjects refuse to stop any beverage or food containing grapefruit 7 days before the first dose; 5. those who have heavy smokers, alcoholics or drug abuse 6. lactating female subjects or fertile female subjects 7. those with clinically significant abnormality of physical examination, vital signs and laboratory test during the screening period.
pegaspargase-coep chemotherapy combined with radiotherapy for extra-nodal nk/t cell lymphoma

Conditions: NK/T Cell Lymphoma Nos

Summary: the optimal first-line treatment for extra-nodal nk/t-cell lymphoma (enktl) has not been well-defined. this phase ii study aimed to evaluate the efficacy and safety of pegaspargase, cyclophosphamide, vincristine, etoposide and prednisone (coepl) regimen combined with radiotherapy for patients with newly diagnosed enktl.


Eligibility criteria:
inclusion criteria: * patients with confirmed pathological diagnosis of enktl as defined by who criteria * age 14-80 years * no prior chemotherapy or radiotherapy * eastern cooperative oncology group (ecog) performance status of 0-2 * at least one measurable lesion * adequate bone marrow function (i.e. hemoglobin ≥80 g/l, absolute neutrophil count ≥ 1.0 × 10\^9/l, platelets ≥ 100 ×10\^9/l), adequate renal function (i.e. serum creatinine ≤177 μmol/l), adequate hepatic function (e.g. total bilirubin ≤ two times the upper limit of normal, and alt /ast ≤2.5 times the upper limit of normal) * expected survival of more than three months exclusion criteria: * invasion of lymphoma to central nervous system * pre-existing coagulation disorder * other concomitant neoplasms * severe infection * positive hiv antibody * hbv dna titer higher than 10\^4 copies /ml in hbsag-positive patients post antiviral therapy * pregnant or lactating women * women of childbearing age unwilling to take contraceptive measures during the study period
oxaliplatin and docetaxel for recurrent or metastatic head and neck cancer

Conditions: Neoplasms; Head and Neck Neoplasms

Summary: patient receiving oxaliplatin and docetaxel will have longer progression free survival than those patients receiving standard care.

oxaliplatin: 130mg/m2 given on day 1 by intravenous injection; and docetaxel: 60mg/m2 given on day 1 by intravenous injection cycles are repeated every 21 days until disease progression, unacceptable toxicity or subject's withdrawal.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed metastatic or locoregionally recurrent scchn deemed incurable by local therapy * measureable disease * no prior use of palliative chemo after the scchn is deemed incurable by local therapy * no prior treatment with oxaliplatin or docetaxel * 18 years of age or older * ecog performance status 0-1 * anc 1,500/mcl or greater * adequate renal function * adequate liver function * recovered from acute and late effects of any prior treatment with a minimum of 4 weeks from the last session to enrollment in the study * patient or their legal representative must be able to read, understand, and provide informed consent * patients of childbearing potential and their partners must agree to use an effective form of contraception during the study and for 90 days following the last dose of study medication exclusion criteria: * patients with an active documented infection or with a fever (38.5 degrees celsius or higher) within 3 days of the first scheduled dose of study treatment * patients with active cns metastases * hypercalcemia related to scchn * history of prior malignancy with the past 5 years except for curatively treated basal cell carcinoma of the skin, cervical intraepithelial neoplasia or localized prostate cancer * patients with known hypersensitivity to any of the components of oxaliplatin or docetaxel or to other drugs formulated with polysorbate 90 * patients receiving concurrent investigational therapy or investigational therapy less than 30 days from first scheduled dose of study therapy * peripheral neuropathy grade 2 or higher * any medical condition deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results * history of allogeneic transplant * known hiv or hepatitis b or c (active, previously treated or both)

Keywords: recurrent disease metastatic disease squamous cell carcinoma multicenter phase ii
prescribing interventions for chronic pain via the electronic health record study - primary care providers

Conditions: Opioid-use Disorder; Opioid Use; Opioid Abuse

Summary: the objective of this research is to assess the effects of electronic health record (ehr)-based decision support tools on primary care provider (pcp) decision-making around pain treatment and opioid prescribing. the decision support tools are informed by principles of "behavioral economics," whereby clinicians are "nudged," though never forced, towards guideline-concordant care.

to test the effects of these decision support tools for improving the quality of care for pain treatment, the investigators will implement a pragmatic clinic-randomized trial across the primary care clinics of fairview medical group and university of minnesota physicians. the study has two parallel components. the decision support tools to be tested will differ somewhat depending on whether a given patient is opioid-naïve, or whether a given patient is a current opioid-user. four sets of analyses will be conducted separately: one for the opioid-naïve group using ehr data, one for the current opioid-user group using ehr data, one at the pcp-level using web survey data, and one at the pcp-level using mn prescription drug monitoring program (pdmp) data.

Eligibility criteria:
inclusion criteria: - all primary care providers from all of the fairview and university of minnesota physicians study clinics exclusion criteria: - primary care providers who work less than 20% full time equivalent (fte)
cocaine use disorder and cortical dopamine

Conditions: Cocaine Dependence

Summary: the goal of this study is to use \[c-11\]flb 457 and amphetamine (oral, 0.5 mg/kg) to measure cortical dopamine transmission in cocaine dependent individuals and healthy controls

this study seeks to examine dopamine (da) transmission in vivo, using positron emission tomography (pet) with \[c-11\]flb 457, in cortical regions of interest in subjects who have a history of cocaine dependence. we hypothesize that cocaine dependence is associated with decreases in dopamine in the prefrontal cortical regions compared to controls. this may explain the impulsivity and cognitive deficits that underlie relapse in this disorder.

Eligibility criteria:
subjects with cocaine dependence inclusion criteria 1. males or females 18-40 2. fulfill diagnostic and statistical manual (dsm-iv) diagnosis for cocaine dependence 3. medically healthy major exclusions 1. major medical, psychiatric, co-morbid drug \& alcohol use disorders 2. pregnancy or lactation, 3. contraindications to mri 4. currently employed as radiation worker; or participation in radioactive drug research protocols within the previous year 5. family history of a psychotic illness or manic episode in first-degree relatives healthy subjects inclusion criteria 1. males or females 18-40 2. absence of present or past psychiatric conditions (including alcohol or drug dependence) 3. a negative urine drug screen 4. medically healthy major exclusions 1. any medical, psychiatric, co-morbid drug \& alcohol use disorders 2. pregnancy or lactation, 3. contraindications to mri 4. currently employed as radiation worker; or participation in radioactive drug research protocols within the previous year 5. family history of a psychotic illness or manic episode, or drug and alcohol abuse/dependence in first-degree relatives
advanced translational research on childhood leukemia

Conditions: Childhood Leukemia

Summary: prognosis of children with leukemia, the most common pediatric cancer, has improved markedly. yet, relapse still occurs in 15-40% of patients with a probability of survival of \<50%, which is unlikely to be boosted by intensification of standard chemotherapy due to overwhelming toxicity. the advent of effective and safe targeted therapies for high-risk cases is therefore imperative. this study constitutes two research projects aiming at driving therapeutic advances.

the first part of the study aimed to investigate genomics and drug sensitivity profiling of childhood leukemia and its potential application for precision medicine. the second part of the study aimed to develop novel antibody for treatment of childhood leukemia by animal model experiments. design: project 1: whole-exome and rna sequencing will be performed on children with leukemia (all, aml, mpal, jmml, mds) prospectively recruited in the hong kong children's hospital. samples will be screened for their sensitivity to preselected, clinically accessible targeted agents in an ex vivo culture system. results for the high-risk patients will be subjected to the tumor broad for evaluation. project 2: fully human antibody candidates identified by phage display will be engineered into therapeutic forms, and assessed for efficacy and safety in patient-derived xenografts of relapsed/refractory b-all and in transgenic mice. the mechanisms of action will be identified by single-cell rna sequencing. significance: implementation of functional genomics could identify leukemia patients who will benefit from targeted therapies and enable tailoring of precision medicine. the invented antibodies could be moved forward into clinical trials for salvaging high-risk pediatric b-all. immediate and long-term impact on therapy of childhood leukemia is foreseen.

Eligibility criteria:
list of inclusion criteria: 1. acute lymphoblastic leukemia (all) or 2. acute myeloid leukemia (aml) or 3 .mixed phenotype acute leukemia (mpal) or 4. juvenile myelomonocytic leukemia (jmml) or 5. myelodysplastic syndromes (mds) or 6. normal bone marrow donor list of exclusion criteria: 1. this study will not recruit subjects who are unable to understand english or chinese. 2. patient or parent refusal
effects aquatic exercises on balance and hand function in multiple sclerosis

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: this study aims to compare and contrast the effects of two different aquatic exercises on postural control and hand functions in people with multiple sclerosis.

impaired limits of stability causes falls in people with multiple sclerosis (pwms) whereas a well-controlled posture provides improved upper limb functions which are limited in almost 75% of pwms due to weakness, spasticity or tremor. it is an already known fact that hand dexterity is an indicator of fall risk due to neuromuscular causes and/or abnormalities in the corpus callosum in pwms. aquatic therapy (at) provides a safe and effective environment for many therapeutic purposes. it is important to understand the effects of each type, intensity, and duration of the aquatic interventions to accomplish most suitable aquatic exercise program. halliwick method, neuromotor treatment approach which uses fluid and mechanical properties of water, is based on postural control by mobilizing and controlling body parts through the ten point program. during aquatic plyometric exercises, proximal part of the body needs to be stabilized to generate a sudden and powerful contraction at the distal part and stabilization of the proximal joints is necessary for maintaining distal movements in a coordinated way. it is important to understand the effects of each type, intensity, and duration of the aquatic interventions to accomplish most suitable aquatic exercise program. this study aims to compare and contrast the effects of two different aquatic exercises on postural control and hand function.

Eligibility criteria:
inclusion criteria: * edss\>6 * volunteered exclusion criteria: * clinical relapse within three months * incontinence * persistent infection

Keywords: aquatic therapy limits of stability halliwick aquatic plyometric exercises